Precision BioSciences stock fell 6.48 percent to USD 5.77 on October 16, 2026
Published on 10/17/2026 at 22:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSStock falls 6.48 percent
- Nasdaq trading ended lower on October 16, 2026.
- Market capitalization stood at USD 159.3 million on October 16, 2026.
- Precision BioSciences stock closed at USD 5.77 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 6.48 percent on the day.
- The price-to-earnings ratio was minus 2.06 on October 16, 2026.
Precision BioSciences stock fell 6.48 percent on October 16, 2026. MarketBeat estimates the next third-quarter results for November 2, 2026, before the market opens. The stock closed at USD 5.77 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 6.48 percent on the day.
November 2 marks the next report
The scheduled report gives investors a defined near-term date for the biotechnology company. MarketBeat lists consensus revenue of USD 1.38 million and a consensus loss of USD 0.85 per share for the third quarter of 2026. The same source lists a conference call for November 6, 2026, at 9:30 a.m. ET.
Price position remains wide
Precision BioSciences traded between USD 5.72 and USD 6.15 during the October 16, 2026 session. Its USD 5.77 close stood 40.02 percent below the USD 9.62 52-week high and 63.46 percent above the USD 3.53 low. Trading volume reached 300,247 shares, compared with an average of 266,620 shares, an increase of 12.63 percent.
Valuation and market comparison
The company had a market capitalization of USD 159.3 million on October 16, 2026. Its price-to-earnings ratio was minus 2.06, while no dividend yield was recorded. Precision BioSciences develops gene-editing therapies through its ARCUS platform and works on programs addressing chronic hepatitis B, Duchenne muscular dystrophy and alpha-1 antitrypsin deficiency.
Comparison with peers
Precision BioSciences (Nasdaq, USD): minus 6.48 percent, P/E minus 2.06, market capitalization USD 159.3 million
Editas Medicine (Nasdaq, USD): minus 3.69 percent, P/E minus 3.14, market capitalization USD 360.9 million
CRISPR Therapeutics (Nasdaq, USD): minus 4.41 percent, P/E minus 10.35, market capitalization USD 4.8 billion
Dates and valuation
The next scheduled reporting date is November 2, 2026, followed by the conference call on November 6, 2026. The earnings estimates place the next report against a current market value of USD 159.3 million and a price-to-earnings ratio of minus 2.06.
Stock closes after a weak session
The October 16, 2026 Nasdaq decline leaves the stock below its 52-week high while the November 2 reporting date provides the next calendar point for the market.
Market context: Market report S&P 500.
